Current Status of Genetic Diagnosis Laboratories and Frequency of Genetic Variants Associated with Cystic Fibrosis Through a Newborn-Screening Program in Turkey

Overview

Journal Genes (Basel)

Publisher MDPI

Date 2021 Feb 12

PMID 33572515

Citations 5

Authors

Sevcan Tug Bozdogan

Cem Mujde

Ibrahim Boga

Ozge Sonmezler

Abdullah Hanta

Cagla Rencuzogullari

Dilek Ozcan

Derya Ufuk Altintas

Atil Bisgin

Affiliations

Soon will be listed here.

Abstract

Background: Cystic fibrosis (CF) is the most common worldwide, life-shortening multisystem hereditary disease, with an autosomal recessive inheritance pattern caused by mutations in the cystic fibrosis transmembrane conductance regulator () gene. The national newborn screening (NBS) program for CF has been initiated in Turkey since 2015. If the immunoreactive trypsinogen (IRT) is elevated (higher than 70 μg/L in the second control) and confirmed by sweat test or clinical findings, genetic testing is performed. The aims of this study are to emphasize the effect of NBS on the status of genetic diagnosis centers with the increasing numbers of molecular testing methods, and to determine the numbers and types of mutations in Turkey.

Methods: The next-generation sequencing (NGS) and multiplex ligation-dependent probe amplification (MLPA) results of 1595 newborns, who were referred to Cukurova University Adana Genetic Diseases Diagnosis and Treatment Center (AGENTEM) for molecular genetic testing, were evaluated with positive CF NBS program results since 2017.

Results: According to the results; 560 (35.1%) of the 1595 patients carried at least 1 (one) CF-related variant, while 1035 patients (64.9%) had no mutation. Compound heterozygosity for two mutations was the most common in patients, while two detected variants were homozygote in 14 patients. A total of 161 variants were detected in 561 patients with mutations. Fifteen novel variants that have not been previously reported were found. Moreover, p.L997F was identified as the most frequent pathogenic mutation that might affect the IRT measurements used for the NBS. The distribution of mutation frequencies in our study showed a difference from those previously reported; for example, the well-known p.F508del was the third most common ( = 42 alleles), rather than the first. The most striking finding is that 313 cases had a pathogenic variant together with the V470M variant, which might have a cumulative effect on CF perpetuation.

Conclusion: This study is the first to determine the mutational spectrum of CFTR in correlation with the NBS program in the Turkish population. NBS for CF raises issues regarding screening in diverse populations, both medical and non-medical benefits, and carrier identification. Through the lens of NBS, we focused on the integrated diagnostic algorithms and their effect on the results of genetic testing.

Citing Articles

A De Novo Missense Variant in Combination with Two Inherited Missense Variants in and Detected in a Patient with Chronic Pancreatitis.

Bontempo P, Surace C, Menale L, Alicata C, DElia G, Tomaiuolo A Biomedicines. 2024; 12(6).

PMID: 38927485 PMC: 11201075. DOI: 10.3390/biomedicines12061278.

Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020-2023).

Therrell B, Padilla C, Borrajo G, Khneisser I, Schielen P, Knight-Madden J Int J Neonatal Screen. 2024; 10(2).

PMID: 38920845 PMC: 11203842. DOI: 10.3390/ijns10020038.

Cystic Fibrosis Foundation Evidence-Based Guideline for the Management of CRMS/CFSPID.

Green D, Lahiri T, Raraigh K, Ruiz F, Spano J, Antos N Pediatrics. 2024; 153(5).

PMID: 38577740 PMC: 11781860. DOI: 10.1542/peds.2023-064657.

Variability of Clinical Presentation in Patients Heterozygous for the F508del Cystic Fibrosis Variant: A Series of Three Cases and a Review of the Literature.

Raymond C, Gaul S, Han S, Huang G, Dong J Cureus. 2023; 15(6):e40185.

PMID: 37431359 PMC: 10329848. DOI: 10.7759/cureus.40185.

Genotype-phenotype correlations of cystic fibrosis in siblings compound heterozygotes for rare variant combinations: Review of literature and case report.

Tkemaladze T, Kvaratskhelia E, Ghughunishvili M, Lentze M, Abzianidze E, Skrahina V Respir Med Case Rep. 2022; 40:101750.

PMID: 36238659 PMC: 9550642. DOI: 10.1016/j.rmcr.2022.101750.

References

Sasihuseyinoglu A, Altintas D, Bisgin A, DoGruel D, Yilmaz M, Serbes M . Two years of newborn screening for cystic fibrosis in Turkey: Çukurova experience. Turk J Pediatr. 2020; 61(4):505-512. DOI: 10.24953/turkjped.2019.04.006. View

Nefzi M, Hadj Fredj S, Tebib N, Barsaoui S, Boussetta K, Siala H . Contribution of M470V variant to cystic fibrosis: First study in CF and normal Tunisian population. Pathol Biol (Paris). 2015; 63(4-5):169-74. DOI: 10.1016/j.patbio.2015.07.004. View

Lucarelli M, Narzi L, Pierandrei S, Bruno S, Stamato A, DAvanzo M . A new complex allele of the CFTR gene partially explains the variable phenotype of the L997F mutation. Genet Med. 2010; 12(9):548-55. DOI: 10.1097/GIM.0b013e3181ead634. View

Strom C, Redman J, Peng M . The dangers of including nonclassical cystic fibrosis variants in population-based screening panels: p.L997F, further genotype/phenotype correlation data. Genet Med. 2011; 13(12):1042-4. DOI: 10.1097/GIM.0b013e318228efb2. View

Dequeker E, Stuhrmann M, Morris M, Casals T, Castellani C, Claustres M . Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders--updated European recommendations. Eur J Hum Genet. 2008; 17(1):51-65. PMC: 2985951. DOI: 10.1038/ejhg.2008.136. View

Svensson A, Chou L, Miller C, Robles J, Swensen J, Voelkerding K . Detection of large rearrangements in the cystic fibrosis transmembrane conductance regulator gene by multiplex ligation-dependent probe amplification assay when sequencing fails to detect two disease-causing mutations. Genet Test Mol Biomarkers. 2010; 14(2):171-4. DOI: 10.1089/gtmb.2009.0099. View

Rommens J, Iannuzzi M, Kerem B, Drumm M, Melmer G, Dean M . Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989; 245(4922):1059-65. DOI: 10.1126/science.2772657. View

Monaghan K, Highsmith W, Amos J, Pratt V, Roa B, Friez M . Genotype-phenotype correlation and frequency of the 3199del6 cystic fibrosis mutation among I148T carriers: results from a collaborative study. Genet Med. 2004; 6(5):421-5. DOI: 10.1097/01.GIM.0000139507.20179.3A. View

Petrova N, Kashirskaya N, Vasilyeva T, Kondratyeva E, Zhekaite E, Voronkova A . Analysis of Mutation Spectrum in Ethnic Russian Cystic Fibrosis Patients. Genes (Basel). 2020; 11(5). PMC: 7288340. DOI: 10.3390/genes11050554. View

10.

Petrova G, Yaneva N, Hrbkova J, Libik M, Savov A, Macek Jr M . Identification of 99% of CFTR gene mutations in Bulgarian-, Bulgarian Turk-, and Roma cystic fibrosis patients. Mol Genet Genomic Med. 2019; 7(8):e696. PMC: 6687650. DOI: 10.1002/mgg3.696. View

11.

Veit G, Da Fonte D, Avramescu R, Premchandar A, Bagdany M, Xu H . Mutation-specific dual potentiators maximize rescue of CFTR gating mutants. J Cyst Fibros. 2019; 19(2):236-244. PMC: 7190413. DOI: 10.1016/j.jcf.2019.10.011. View

12.

De Boeck K, Zolin A, Cuppens H, Olesen H, Viviani L . The relative frequency of CFTR mutation classes in European patients with cystic fibrosis. J Cyst Fibros. 2014; 13(4):403-9. DOI: 10.1016/j.jcf.2013.12.003. View

13.

Bobadilla J, Macek Jr M, Fine J, Farrell P . Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. Hum Mutat. 2002; 19(6):575-606. DOI: 10.1002/humu.10041. View

14.

Sofia V, Surace C, Terlizzi V, Da Sacco L, Alghisi F, Angiolillo A . Trans-heterozygosity for mutations enhances the risk of recurrent/chronic pancreatitis in patients with Cystic Fibrosis. Mol Med. 2018; 24(1):38. PMC: 6062922. DOI: 10.1186/s10020-018-0041-6. View

15.

Banjar H, Tuleimat L, El Seoudi A, Mogarri I, Alhaider S, Nizami I . Genotype patterns for mutations of the cystic fibrosis transmembrane conductance regulator gene: a retrospective descriptive study from Saudi Arabia. Ann Saudi Med. 2020; 40(1):15-24. PMC: 7012030. DOI: 10.5144/0256-4947.2020.15. View

16.

Wang Y, Wrennall J, Cai Z, Li H, Sheppard D . Understanding how cystic fibrosis mutations disrupt CFTR function: from single molecules to animal models. Int J Biochem Cell Biol. 2014; 52:47-57. DOI: 10.1016/j.biocel.2014.04.001. View

17.

LaRusch J, Jung J, General I, Lewis M, Park H, Brand R . Mechanisms of CFTR functional variants that impair regulated bicarbonate permeation and increase risk for pancreatitis but not for cystic fibrosis. PLoS Genet. 2014; 10(7):e1004376. PMC: 4102440. DOI: 10.1371/journal.pgen.1004376. View

18.

Suaud L, Yan W, Rubenstein R . Abnormal regulatory interactions of I148T-CFTR and the epithelial Na+ channel in Xenopus oocytes. Am J Physiol Cell Physiol. 2006; 292(1):C603-11. DOI: 10.1152/ajpcell.00088.2006. View

19.

Terlizzi V, Castaldo G, Salvatore D, Lucarelli M, Raia V, Angioni A . Genotype-phenotype correlation and functional studies in patients with cystic fibrosis bearing CFTR complex alleles. J Med Genet. 2016; 54(4):224-235. DOI: 10.1136/jmedgenet-2016-103985. View

20.

Veit G, Avramescu R, Chiang A, Houck S, Cai Z, Peters K . From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. Mol Biol Cell. 2016; 27(3):424-33. PMC: 4751594. DOI: 10.1091/mbc.E14-04-0935. View